Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded …
…, O Schönborn-Kellenberger… - The Lancet Infectious …, 2022 - thelancet.com
Background Additional safe and efficacious vaccines are needed to control the COVID-19
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
[HTML][HTML] Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial
…, G Quintini, O Schönborn‑Kellenberger… - Wiener Klinische …, 2021 - Springer
Background We used the RNActive® technology platform (CureVac NV, Tübingen, Germany)
to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding …
to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding …
Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers
…, S Müller, G Quintini, O Schönborn-Kellenberger… - MedRxiv, 2020 - medrxiv.org
There is an urgent need for vaccines to counter the COVID-19 pandemic due to infections
with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from …
with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from …
[HTML][HTML] A phase I study of the pan-notch inhibitor CB-103 for patients with advanced adenoid cystic carcinoma and other tumors
…, J Cortes, O Schönborn-Kellenberger… - Cancer Research …, 2023 - AACR
Purpose: CB-103 selectively inhibits the CSL–NICD (Notch intracellular domain) interaction
leading to transcriptional downregulation of oncogenic Notch pathway activation. This dose-…
leading to transcriptional downregulation of oncogenic Notch pathway activation. This dose-…
Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers.
…, J Cortes, R Ferrarotto, O Schönborn-Kellenberger… - 2021 - ascopubs.org
3020 Background: CB-103 selectively inhibits the CSL-NICD interaction leading to down-regulation
of CSL-NICD mediated oncogenic pathway activation downstream of NOTCH …
of CSL-NICD mediated oncogenic pathway activation downstream of NOTCH …
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate: results from herald, a phase 2b/3, randomised, observer-blinded, placebo-controlled …
…, X Sáez-Llorens, O Schönborn-Kellenberger… - 2021 - papers.ssrn.com
Methods: HERALD is an ongoing phase 2b/3 randomised, observer-blinded, placebo-controlled
clinical trial in ten countries in Europe and Latin America. SARS-CoV-2 naïve adults …
clinical trial in ten countries in Europe and Latin America. SARS-CoV-2 naïve adults …
First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody HDIT101 in healthy …
…, R Laage, O Schönborn‐Kellenberger… - Clinical and …, 2022 - Wiley Online Library
HDIT101 is a first‐in‐class humanized monoclonal antibody recognizing a conserved epitope
in glycoprotein B, a target present on the surface of herpes simplex virus 1 (HSV‐1) and …
in glycoprotein B, a target present on the surface of herpes simplex virus 1 (HSV‐1) and …
[PDF][PDF] First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood …
…, D Rossi, N Spardy Burr, O Schönborn-Kellenberger… - J. Clin. Oncol, 2018 - cellestia.com
BACKGROUND NOTCH signalling is a key development pathway whose aberrant
activation is recognised to play an oncogenic role in numerous human solid cancers and …
activation is recognised to play an oncogenic role in numerous human solid cancers and …
A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination …
…, PA Cassier, R Lobbardi, O Schönborn-Kellenberger… - 2023 - ascopubs.org
TPS3163 Background: BRAF is a protein kinase that acts as a signal transducer in the
MAPK pathway. Mutant BRAF V600 is capable of uncontrolled signaling and is constitutively …
MAPK pathway. Mutant BRAF V600 is capable of uncontrolled signaling and is constitutively …
MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a …
…, M Dymkowska, C Andrieu, O Schönborn-Kellenberger… - Blood, 2023 - Elsevier
BACKGROUND: The development of targeted immunotherapy for acute myeloid leukemia (AML)
is challenging due to the clonal heterogeneity of the disease and the lack of single AML…
is challenging due to the clonal heterogeneity of the disease and the lack of single AML…